LIMINATUS PHARMA, INC. (LIMN)

LIMINATUS PHARMA, INC. (LIMN) scores 43 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is $0.00. Quantitative score: 43/100. Qualitative score: 70/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full LIMN analysis on boothcheck